Q3 Sales rise by over 305% to $8.3m
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The growth is attributed to the Nutritionals business and a strategic partnership with Rockcheck Group for Danone products. Chairman Anthony Noble highlighted the company's recovery and the introduction of new sales channels, which are expected to contribute to future revenue growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Xenitra
- Acquisition of Fukang OTC Pharmacy
- OPAL Token & Xen Shop Launch - Next-Gen Digital Commerce
- $30m Danone - Rockcheck Strategic Partnership
- Half Yearly Report and Accounts
- EZZ: EZZ Appoints Aumake in $10m Exclusive Dist Agreement
Later from Xenitra
- OPAL token launch of EZZ products sells $100k in first week
- $1.25m Raised to Support Next Phase of Growth
- Product sales of $500k in first month of OPAL token launch
- XEN Appointed as Exclusive Biomiq Skincare China Distributor
- $1.1m in OPAL-Tokenised Product Sales in First 7 Weeks
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra